Aripiprazole in schizophrenia: consensus guidelines.

@article{Travis2005AripiprazoleIS,
  title={Aripiprazole in schizophrenia: consensus guidelines.},
  author={Michael J. Travis and Tom Burns and Serdar M. Dursun and Thomas Fahy and Sofia Frangou and Richard Gray and Peter M. Haddad and Robert Hunter and David McD Taylor and Allan Hunter Young},
  journal={International journal of clinical practice},
  year={2005},
  volume={59 4},
  pages={485-95}
}
Schizophrenia is a chronic disabling disease which in the majority of cases requires long-term treatment with antipsychotic medication. Before the development of atypical antipsychotics, treatment choice was restricted to conventional (or typical) antipsychotics, which are known to cause a range of side effects including extrapyramidal symptoms. Although atypical agents provide a favourable alternative (advocated by the National Institute of Clinical Excellence in the UK), they are associated… CONTINUE READING